Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18082561 | 0.85 | HRH3 (0.50) | ALDH1A1KDM4EMAPTHTTMEN1 | |
| SCHEMBL12203 | 0.83 | CHRM2 (0.55) | ALDH1A1KDM4EMAPTHTTACHE | |
| SCHEMBL11002867 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTHTTGBA1 | |
| SCHEMBL22702113 | 0.79 | CYP11B1 (0.44) | ALDH1A1MEN1KMT2ACHRM2CHRM3 | |
| SCHEMBL12449575 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1KMT2AACHE | |
| SCHEMBL17285919 | 0.78 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTGBA1MEN1 | |
| SCHEMBL16316076 | 0.77 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTHTTGBA1 | |
| SCHEMBL31546411 | 0.77 | HRH3 (0.69) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL12981 | 0.77 | HRH3 (0.69) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL15587395 | 0.76 | MAP4K4 (0.43) | ALDH1A1MEN1KMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ALDH1A1 2149/4885KDM4E 1288/4885MAPT 4689/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | ALDH1A1 2149/4885KDM4E 1288/4885MAPT 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.